Neurofibromatosis 1
Rare Disease·MeSH: Neurofibromatosis 1
Prevalence
30.0 / 100K
1 drug in development·1 company·9 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Selumetinib | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Neurofibromatosis 1?
BioSniper tracks 1 drug in development for Neurofibromatosis 1 across 1 company.
How many clinical trials target Neurofibromatosis 1?
There are 9 clinical trials targeting Neurofibromatosis 1 tracked by BioSniper.
What is the prevalence of Neurofibromatosis 1?
The estimated prevalence of Neurofibromatosis 1 is approximately 30.0 per 100,000 population.
Deep-dive into Neurofibromatosis 1
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis